FDA approves enlicitide (Lipfendra), the first oral PCSK9 inhibitor for lowering blood cholesterol
The FDA has approved enlicitide, sold as Lipfendra, as the first oral PCSK9 inhibitor for lowering blood cholesterol. The national approval gives patients a pill option in a drug class previously available only by injection. Its real-world impact will depend on insurance coverage and physician adoption, and actual effectiveness and adherence outside trials remain to be seen.
Why it matters
High cholesterol remains a major driver of cardiovascular disease, and an oral PCSK9 inhibitor could make this drug class accessible to patients who cannot or will not take injections.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news